A recent study has found that higher serum levels of B-cell activating factor and anti-CCP3 are associated with a reduced risk of developing chronic lymphocytic leukemia (CLL), suggesting potential ...

Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...

High-frequency, low-dose rituximab achieved ~85% peripheral CLL clearance within 1 hour and ~34% nodal reduction in 1 week, with macrophage phagocytosis and complement as dominant mechanisms.

Project Renewal updates older oncology drug labels to ensure clinical relevance and scientific accuracy, involving external experts and early-career scientists. Fludarabine phosphate's updated label ...

About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

Active surveillance, or watchful waiting, is often recommended for people with slow-growing CLL who do not have symptoms. Targeted therapies, such as BTK and BCL-2 inhibitors, are common treatments ...

Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.

Imbruvica (ibrutinib) is a brand-name drug that’s prescribed for chronic lymphocytic leukemia (CLL). This article covers topics such as side effects, dosage, and how Imbruvica works. Imbruvica is ...

Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...